-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

Benzinga·05/21/2026 10:06:23
Listen to the news
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.